TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8103272
Drug: Topical cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporin A (8% w/v)
Study: 3714757
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tiropramide
Study: 3714757
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg trimebutine maleate
Study: 3714757
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg octilonium bromide
Study: 30203841
Drug: Avatrombopag 20
Normalized name: avatrombopag 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avatrombopag 20 mg daily for 14 days
Study: 30203841
Drug: Avatrombopag (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avatrombopag (1, 3, 10, 20, 50, 75 and 100 mg)
Study: 30203841
Drug: Avatrombopag (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avatrombopag (3, 10 and 20 mg)
Study: 26321236
Drug: Pooled pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled pacing therapy
Study: 23889105
Drug: 2 g intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g intravenous Cefazoline administered prior to skin incision
Study: 23889105
Drug: 2 g intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g intravenous Cefazoline administered immediately after cord clamping
Study: 22134627
Drug: Polysporin Triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysporin Triple ointment (P(3))
Study: 18097177
Drug: Orbital radiotherapy
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital radiotherapy combined with oral corticosteroids
Study: 18097177
Drug: Orbital radiotherapy
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital radiotherapy combined with intravenous methylprednisolone
Study: 15966883
Drug: AmF/SnF(2) dentifrice-mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmF/SnF(2) dentifrice-mouth rinse combination
Study: 10471987
Drug: Cisapride with
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisapride with Pantoprazole (40 mg)
Study: 8335505
Drug: IFN-alpha priming
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha priming followed by IFN-alpha therapy (10 MU thrice-weekly for three months)
Study: 8335505
Drug: IFN-alpha therapy
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha therapy (10 MU thrice-weekly for three months)
Study: 3743147
Drug: Instillation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of 50 ml of 0.1 N hydrochloric acid in Group 3
Study: 3743147
Drug: Atropine pretreatment
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine pretreatment (0.01 mg/kg twice daily) followed by instillation of acid in Group 3
Study: 3743147
Drug: Instillation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of 50 ml of isotonic sodium chloride solution
Study: 30863141
Drug: Methoxyflurane (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxyflurane (up to 6 mL)
Study: 22679908
Drug: Tianeptine (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (37.5 mg) with probiotics (Bacillus subtilis + Streptococcus faecium)
Study: 22679908
Drug: Amitriptyline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (10 mg) with probiotics (Bacillus subtilis + Streptococcus faecium)
Study: 20081065
Drug: Single ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose (SAD) of edoxaban (10, 30, 60, 90, 120, 150 mg)
Study: 20081065
Drug: Multiple ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending dose (MAD) of edoxaban (90 mg daily, 60 mg twice daily, 120 mg daily)
Study: 15951655
Drug: Tiagabine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (maximum dose 24 mg/day)
Study: 11251695
Drug: Gabapentin (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (2400 mg/day)
Study: 8934107
Drug: 2500 XaI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2500 XaI units of low molecular weight heparin daily
Study: 8934107
Drug: 5000 XaI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 XaI units of low molecular weight heparin daily
Study: 1930768
Drug: Methanol exposure
Normalized name: methanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methanol exposure at 250 mg/m3 for 75 minutes
Study: 6131124
Drug: Using psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using psychotropic drugs (benzodiazepines)
Study: 31123862
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g bovine colostrum for 4.5 hours
Study: 31123862
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g bovine colostrum per day for 4 weeks
Study: 31123862
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g bovine colostrum per day for 12 weeks
Study: 31271359
Drug: Reduced unit
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced unit dose of rabies immunoglobulin (RIG) for class 3 rabid animal bites
Study: 17552299
Drug: Conventional restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional restorative treatment using rotary instruments (750 rpm)
Study: 15117306
Drug: Pyrimethamine-sulphadoxine plus
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine-sulphadoxine plus probenecid (20-25 mg/kg in two divided doses daily for 3 days)
Study: 15117306
Drug: Pyrimethamine-sulphadoxine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine-sulphadoxine (25 mg/kg of the sulphadoxine component)
Study: 7803248
Drug: IVIg 500
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg 500 mg/kg every 4 weeks for 1 year
Study: 7803248
Drug: IVIg 250
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg 250 mg/kg every 4 weeks for 1 year
Study: 31553946
Drug: 5A's model
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5A's model for PA counseling with weekly motivational text messages
Study: 16430010
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L‐Pop
Study: 17159028
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for glaucoma (cataract extraction)
Study: 17159028
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment for glaucoma
Study: 12897178
Drug: L-NAME (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (4 mg kg-1 in 50 ml saline over 60 min)
Study: 12897178
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without L-NAME)
Study: 1528102
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA (IPCA)
Study: 30975627
Drug: Erlotinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib plus bevacizumab (150 mg per day erlotinib + 15 mg/kg bevacizumab once every 21 days)
Study: 30975627
Drug: Erlotinib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib alone (150 mg per day)
Study: 29905969
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation, adjusted to maintain serum 25(OH)D above 75 nmol/L
Study: 26725183
Drug: Pemetrexed plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed plus Cisplatin followed by Gefitinib (PC/G)
Study: 26809984
Drug: Gefitinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib monotherapy (G)
Study: 25168762
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sports-oriented exercise programme and web-delivered self-help tool
Study: 22442436
Drug: Pulsed dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pulsed dexamethasone (6 monthly pulses)
Study: 22442436
Drug: Daily prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily prednisolone (8 months)
Study: 22442436
Drug: Daily prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily prednisolone
Study: 22442436
Drug: None (treatment-nonresponsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: None (treatment-nonresponsive patients)
Study: 17700050
Drug: Brief Dynamic
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Dynamic Therapy (BDT) combined with antidepressants
Study: 17700050
Drug: Supportive Psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Psychotherapy (BSP) combined with antidepressants
Study: 11820944
Drug: Albuterol +
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol + Ipratropium
Study: 8674228
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (200 micrograms applied to one nostril daily for 3 weeks)
Study: 8674228
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (200 micrograms applied to one nostril daily for 3 weeks)
Study: 21077346
Drug: Nifedipine CR
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine CR (NCR) dose uptitration (VAL 80 mg + NCR 40 mg)
Study: 21077346
Drug: Valsartan (VAL)
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan (VAL) dose uptitration (VAL 160 mg + NCR 20 mg)
Study: 21077346
Drug: Nifedipine CR
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine CR (NCR) dose uptitration
Study: 21077346
Drug: Valsartan (VAL)
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan (VAL) dose uptitration
Study: 17568867
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg/day for three days, n = 49)
Study: 17568867
Drug: Amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (500 mg every eight hours for ten days, n = 53)
Study: 9813870
Drug: Oral Mg
Normalized name: cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Mg supplementation (500 mg Mg-oxide.d-1 for 3 weeks)
Study: 7710435
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (20 mg isosorbide-5-mononitrate, oral)
Study: 7710435
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (20 mg isosorbide-5-mononitrate, oral)
Study: 7710435
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C (20 mg isosorbide-5-mononitrate, intravenous)
Study: 30473139
Drug: Spironolactone 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 12.5 mg daily
Study: 27646835
Drug: sacubitril/valsartan 97/103
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan 97/103 mg two times daily
Study: 27646835
Drug: irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: irbesartan 300 mg one time daily
Study: 23642942
Drug: Panax notoginseng
Normalized name: PANAX NOTOGINSENG TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panax notoginseng 4000 mg capsules
Study: 21942957
Drug: If channel
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If channel inhibitor ivabradine (12.1±2.3 mg/day)
Study: 21942957
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release metoprolol succinate (59.1±4.5 mg/day)
Study: 31493104
Drug: TRUS-PNB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRUS-PNB group receiving 60 mg lidocaine gel intrarectally and infiltration of a prilocaine and bupivacaine mixture (5 mL of 2% prilocaine + 5 mL of 0.25% bupivacaine).
Study: 25213774
Drug: AMG 811
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 811 (180 mg SC)
Study: 18830192
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 2 g of magnesium sulfate
Study: 14764128
Drug: Duloxetine 40
Normalized name: duloxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 40 mg twice daily for 12 weeks
Study: 9151061
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no drug regimen specified)
Study: 8423888
Drug: Bromocriptine (Br)
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine (Br) monotherapy
Study: 8423888
Drug: Levodopa (LD)
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa (LD) monotherapy
Study: 8423888
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Br and LD)
Study: 19400981
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (duration: 4 weeks)
Study: 19400981
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (1-2 weeks)
Study: 7761011
Drug: Peridural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peridural morphine hydrochloride (0.5 mg/kg)
Study: 3051332
Drug: Glycosaminoglycan polysulphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycosaminoglycan polysulphate (GAGPS) treatment
Study: 25989216
Drug: Mangiferin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mangiferin (150 mg/day)
Study: 18638711
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine therapy (WM) including voltaren extended action tablet, methotrexate, and sulfasalazine
Study: 18638711
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine therapy (CM) including Glucosidorum Tripterygll Totorum tablet and Yishen Juanbi Tablet
Study: 18638711
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine therapy (CM)
Study: 16122909
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment (IT)
Study: 15072604
Drug: Bicalutamide as
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide as immediate therapy
Study: 11109422
Drug: HCT/amiloride 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCT/amiloride 50 mg/5 mg
Study: 9182081
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral flosequinan after 10 days of treatment
Study: 30419911
Drug: Routine daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine daily care during radiotherapy treatment (Control)
Study: 26453951
Drug: Comprehensive self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive self-management (CSM) program combining cognitive behavioral therapy with relaxation and dietary strategies; 9 sessions (1 hour each) over 13 weeks
Study: 21780085
Drug: Aluminum chloride
Normalized name: Aluminum Chloride
DrugBank: Aluminum chloride (DB11081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum chloride (20 mM) injections daily from E12 to E15
Study: 21780085
Drug: Aluminum chloride
Normalized name: Aluminum Chloride
DrugBank: Aluminum chloride (DB11081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum chloride (2 mM) injections daily from E12 to E15
Study: 21433319
Drug: Prostamol Uno
Normalized name: unoprostone
DrugBank: Unoprostone (DB06826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostamol Uno (PU) 320 mg/day for 36 months
Study: 11206864
Drug: Rizatriptan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan (10 mg)
Study: 11061582
Drug: Zolmitriptan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan (2.5 mg)
Study: 1557928
Drug: Two-component pertussis
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-component pertussis vaccine (containing pertussis toxoid and filamentous haemagglutinin)
Study: 29968397
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg baclofen
Study: 26050104
Drug: Itolizumab 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itolizumab 0.2 mg/kg weekly with methotrexate
Study: 26050104
Drug: Itolizumab 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itolizumab 0.4 mg/kg weekly with methotrexate
Study: 26050104
Drug: Itolizumab 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itolizumab 0.8 mg/kg weekly with methotrexate
Study: 20142538
Drug: Fixed-combination latanoprost-timolol
Normalized name: latanoprost / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination latanoprost-timolol (FCLT)
Study: 17356043
Drug: Conventional GH
Normalized name: LINER,SECURELY YOURS,PAPER PAK #GH-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional GH dose of 40 microg/kg/d (n = 34)
Study: 15699378
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg/day administered three times daily (TID)
Study: 15699378
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg/day administered twice daily (BID)
Study: 15699378
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg/day administered TID
Study: 15699378
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg/day administered BID
Study: 11889661
Drug: Clonazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.5 mg/night)
Study: 11889661
Drug: Cyclobenzaprine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine (10 mg/night)
Study: 7842192
Drug: No inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: No inhaled corticosteroids (Control)
Study: 2121114
Drug: Nitroglycerin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (5 mg intravenous infusion for 60 minutes)
Study: 650201
Drug: Marijuana extract
Normalized name: marijuana pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana extract cookies (0.3 mg/kg delta‐9‐tetrahydrocannabinol)
Study: 31566486
Drug: Concurrent laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent laparoscopic cholecystectomy and endoscopic retrograde cholangiopancreatography (ERCP)
Study: 21632099
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment (surgery and chemotherapy) for White patients
Study: 21632099
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment (surgery and chemotherapy) for African-American patients
Study: 21632099
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery and chemotherapy for both racial groups
Study: 19081121
Drug: Ivermectin and
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin and albendazole combination (total of 400mg)
Study: 16720865
Drug: Monomeric contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monomeric contrast agent
Study: 16720865
Drug: Dimeric contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimeric contrast agent
Study: 7731155
Drug: Both contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both contrast agents
Study: 10890578
Drug: Cerivastatin 0.8
Normalized name: cerivastatin 0.8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.8 mg after an overnight fast (8 a.m. dosing)
Study: 10890578
Drug: Cerivastatin 0.8
Normalized name: cerivastatin 0.8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.8 mg with a high-fat breakfast (8 a.m. dosing)
Study: 10890578
Drug: Cerivastatin 0.8
Normalized name: cerivastatin 0.8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.8 mg with evening meal (6 p.m. dosing, low-fat)
Study: 10890578
Drug: Cerivastatin 0.8
Normalized name: cerivastatin 0.8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.8 mg 4 hours after dinner (10 p.m. dosing)
Study: 3158124
Drug: Kamillosan cream
Normalized name: Kamillosan
DrugBank: Levomenol (DB13153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kamillosan cream
Study: 31238925
Drug: Intra-articular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular steroid (IAS) injections
Study: 21810747
Drug: Intravenous mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mannitol (1.5 g/kg followed by 0.5 g/kg every 8 hours; n = 30)
Study: 21810747
Drug: No adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjunctive therapy (n = 31)
Study: 11525086
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with sulphonylurea derivatives or metformin
Study: 9145887
Drug: Teicoplanin 6
Normalized name: teicoplanin 66.7 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 6 mg x kg(‐1) intravenously at induction of anesthesia